약물 종류별 알츠하이머 치료 시장 세분화(독립형 약물[콜린에스테라아제 억제제 및 N-메틸-D-아스파르테이트 길항제] 및 복합 약물); 유통 채널별(오프라인[병원 약국 및 소매 약국] 및 온라인); 제품별(웨어러블 및 비웨어러블); 최종 사용자별(병원 진료소 요양원 및 재택 간호 환경) - 산업 수요 분석 및 기회 전망 2027

Global Alzheimer’s Treatment Market

1. Introduction

1.1. Market Definition

1.2. Market Segmentation

1.3. Product Overview

2. Assumptions And Acronyms

3. Research Methodology

3.1. Research Process

3.2. Primary Research

· Manufacturer Front

· Supplier/Distributor Front

· End User Front

3.3. Secondary Research

3.4. Market Size Estimation

4. Executive Summary- Global Alzheimer’s Treatment Market

5. Analysis Of Market Dynamics

5.1. Growth Drivers

5.2. Key Trends

6. Key Market Opportunities

7. Major Roadblocks For The Market Growth

8. Regulatory Landscape

9. Industry Risk Analysis

9.1. Demand Risk Analysis

9.2. Supply Risk Analysis

10. Epidemiology Analysis

11. Patent Analysis

12. Clinical TrialsAnalysis

13. Comparative Analysis Of Treatment Devices In Development

14. Global Alzheimer’s Treatment Market Outlook

14.1. Market Size And Forecast, 2018-2027

14.1.1. By Value (USD Million)

14.2. Global Alzheimer’s Treatment Market Segmentation, 2018-2027

14.2.1. By Treatment

14.2.1.1. By Drug Class

O Standalone Drugs, 2018-2027 (USD Million)

§ Cholinesterase Inhibitors, 2018-2027 (USD Million)

 § Donepezil (Aricept), 2018-2027 (USD Million)

 § Galantamine (Razadyne), 2018-2027 (USD Million)

 § Rivastigmine (Exelon), 2018-2027 (USD Million)

§ N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)

O Combination Drugs, 2018-2027 (USD Million)

14.2.1.2. By Distribution Channel

O Online, 2018-2027 (USD Million)

O Offline, 2018-2027 (USD Million)

§ Hospital Pharmacy, 2018-2027 (USD Million)

§ Retail Pharmacy, 2018-2027 (USD Million)

14.2.2.By Medical Device

14.2.2.1. By Product

O Wearable Device, 2018-2027 (USD Million)

O Non-Wearable Device, 2018-2027 (USD Million)

14.2.2.2.By End-User

O Hospitals, 2018-2027 (USD Million)

O Clinics, 2018-2027 (USD Million)

O Nursing Homes, 2018-2027 (USD Million)

O Home-Care Settings, 2018-2027 (USD Million)

14.2.3.By Region

14.2.3.1. North America Alzheimer’s Treatment Market, 2018-2027 (USD Million)

14.2.3.1.1.Market Overview

14.2.3.1.2.Market Size, 2018-2027 (USD Million)

14.2.3.1.3.Assessment Of Macroeconomic Factors

14.2.3.1.4.Market Segmentation

§ By Treatment

O By Drug Class

§ Standalone Drugs, 2018-2027 (USD Million)

· Cholinesterase Inhibitors, 2018-2027 (USD Million)

· Donepezil (Aricept), 2018-2027 (USD Million)

 · Galantamine (Razadyne), 2018-2027 (USD Million)

 · Rivastigmine (Exelon), 2018-2027 (USD Million)

· N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)

§ Combination Drugs, 2018-2027 (USD Million)

O By Distribution Channel

§ Online, 2018-2027 (USD Million)

§ Offline, 2018-2027 (USD Million)

· Hospital Pharmacy, 2018-2027 (USD Million)

· Retail Pharmacy, 2018-2027 (USD Million)

§ By Medical Device

O By Product

§ Wearable Device, 2018-2027 (USD Million)

§ Non-Wearable Device, 2018-2027 (USD Million)

O By End-User

§ Hospitals, 2018-2027 (USD Million)

§ Clinics, 2018-2027 (USD Million)

§ Nursing Homes, 2018-2027 (USD Million)

§ Home-Care Settings, 2018-2027 (USD Million)

§ By Country

O Us, 2018-2027 (USD Million)

O Canada, 2018-2027 (USD Million)

14.2.3.2.Europe Alzheimer’s Treatment Market, 2018-2027 (USD Million)

14.2.3.2.1.Market Overview

14.2.3.2.2. Market Size, 2018-2027 (USD Million)

14.2.3.2.3. Assessment Of Macroeconomic Factors

14.2.3.2.4. Market Segmentation

§ By Treatment

O By Drug Class

§ Standalone Drugs, 2018-2027 (USD Million)

· Cholinesterase Inhibitors, 2018-2027 (USD Million)

· Donepezil (Aricept), 2018-2027 (USD Million)

· Galantamine (Razadyne), 2018-2027 (USD Million)

· Rivastigmine (Exelon), 2018-2027 (USD Million)

· N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)

§ Combination Drugs, 2018-2027 (USD Million)

O By Distribution Channel

§ Online, 2018-2027 (USD Million)

§ Offline, 2018-2027 (USD Million)

· Hospital Pharmacy, 2018-2027 (USD Million)

· Retail Pharmacy, 2018-2027 (USD Million)

§ By Medical Device

O By Product

§ Wearable Device, 2018-2027 (USD Million)

§ Non-Wearable Device, 2018-2027 (USD Million)

O By End-User

§ Hospitals, 2018-2027 (USD Million)

§ Clinics, 2018-2027 (USD Million)

§ Nursing Homes, 2018-2027 (USD Million)

§ Home-Care Settings, 2018-2027 (USD Million)

§ By Country

O Uk, 2018-2027 (USD Million)

O Germany, 2018-2027 (USD Million)

O Italy, 2018-2027 (USD Million)

O France, 2018-2027 (USD Million)

O Spain, 2018-2027 (USD Million)

O Russia, 2018-2027 (USD Million)

O Rest Of Europe, 2018-2027 (USD Million)

14.2.3.3. Asia Pacific Alzheimer’s Treatment Market, 2018-2027 (USD Million)

14.2.3.3.1. Market Overview

14.2.3.3.2. Market Size, 2018-2027 (USD Million)

14.2.3.3.3. Assessment Of Macroeconomic Factors

14.2.3.3.4. Market Segmentation

§ By Treatment

O By Drug Class

§ Standalone Drugs, 2018-2027 (USD Million)

· Cholinesterase Inhibitors, 2018-2027 (USD Million)

· Donepezil (Aricept), 2018-2027 (USD Million)

· Galantamine (Razadyne), 2018-2027 (USD Million)

· Rivastigmine (Exelon), 2018-2027 (USD Million)

· N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)

§ Combination Drugs, 2018-2027 (USD Million)

O By Distribution Channel

§ Online, 2018-2027 (USD Million)

§ Offline, 2018-2027 (USD Million)

· Hospital Pharmacy, 2018-2027 (USD Million)

· Retail Pharmacy, 2018-2027 (USD Million)

§ By Medical Device

O By Product

§ Wearable Device, 2018-2027 (USD Million)

§ Non-Wearable Device, 2018-2027 (USD Million)

O By End-User

§ Hospitals, 2018-2027 (USD Million)

§ Clinics, 2018-2027 (USD Million)

§ Nursing Homes, 2018-2027 (USD Million)

§ Home-Care Settings, 2018-2027 (USD Million)

§ By Country

O China, 2018-2027 (USD Million)

O India, 2018-2027 (USD Million)

O Japan, 2018-2027 (USD Million)

O South Korea, 2018-2027 (USD Million)

O Indonesia, 2018-2027 (USD Million)

O Australia, 2018-2027 (USD Million)

O Rest Of Asia Pacific, 2018-2027 (USD Million)

14.2.3.4.Latin America Alzheimer’s Treatment Market, 2018-2027 (USD Million)

14.2.3.4.1.Market Overview

14.2.3.4.2. Market Size, 2018-2027 (USD Million)

14.2.3.4.3. Assessment Of Macroeconomic Factors

14.2.3.4.4. Market Segmentation

§ By Treatment

O By Drug Class

§ Standalone Drugs, 2018-2027 (USD Million)

· Cholinesterase Inhibitors, 2018-2027 (USD Million)

· Donepezil (Aricept), 2018-2027 (USD Million)

· Galantamine (Razadyne), 2018-2027 (USD Million)

· Rivastigmine (Exelon), 2018-2027 (USD Million)

· N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)

§ Combination Drugs, 2018-2027 (USD Million)

O By Distribution Channel

§ Online, 2018-2027 (USD Million)

§ Offline, 2018-2027 (USD Million)

· Hospital Pharmacy, 2018-2027 (USD Million)

· Retail Pharmacy, 2018-2027 (USD Million)

§ By Medical Device

O By Product

§ Wearable Device, 2018-2027 (USD Million)

§ Non-Wearable Device, 2018-2027 (USD Million)

O By End-User

§ Hospitals, 2018-2027 (USD Million)

§ Clinics, 2018-2027 (USD Million)

§ Nursing Homes, 2018-2027 (USD Million)

§ Home-Care Settings, 2018-2027 (USD Million)

§ By Country

O Brazil, 2018-2027 (USD Million)

O Mexico, 2018-2027 (USD Million)

O Rest Of Latin America, 2018-2027 (USD Million)

14.2.3.5. Middle East & Africa Alzheimer’s Treatment Market, 2018-2027 (USD Million)

14.2.3.5.1.Market Overview

14.2.3.5.2. Market Size, 2018-2027 (USD Million)

14.2.3.5.3. Assessment Of Macroeconomic Factors

14.2.3.5.4. Market Segmentation

§ By Treatment

O By Drug Class

§ Standalone Drugs, 2018-2027 (USD Million)

· Cholinesterase Inhibitors, 2018-2027 (USD Million)

· Donepezil (Aricept), 2018-2027 (USD Million)

· Galantamine (Razadyne), 2018-2027 (USD Million)

· Rivastigmine (Exelon), 2018-2027 (USD Million)

· N-Methyl-D-Aspartate (Nmda) Antagonist, 2018-2027 (USD Million)

§ Combination Drugs, 2018-2027 (USD Million)

O By Distribution Channel

O By Product

O By End-User

§ By Country

O Israel, 2018-2027 (USD Million)

O Saudi Arabia, 2018-2027 (USD Million)

O UAE, 2018-2027 (USD Million)

O South Africa, 2018-2027 (USD Million)

O Rest Of Middle East & Africa, 2018-2027 (USD Million)

15.Competitive Structure

15.1.Detailed Overview

15.2.Market Share

15.3.Assessment Of Key Product Offerings

15.4.Analysis Of Growth Strategies

15.5. Key Collaborations And Joint Ventures

15.6. Key Mergers And Acquisitions

15.7. Recent News And Developments

15.8. Key Clients And Partners

15.9. Exhaustive Analysis On Key Financial Indicators

15.10. Company Profiles Of Global Alzheimer’s Treatment Market

15.10.1. Neuroem Therapeutics, Inc.

15.10.2. Neuronix

15.10.3. Daiichi Sankyo Company Limited

15.10.4.H. Lundbeck A/S

15.10.5.Pfizer Inc.

15.10.6.Abbvie Inc

15.10.7.Eli Lilly And Company

15.10.8.Allergan, Inc.

15.10.9.Janssen Pharmaceuticals, Inc.

15.10.10. Other Market Players Strategic 16. Recommendations